XML 39 R10.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Goodwill and Other Intangible Assets | 12 Months Ended
--- | ---
Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
| As of December 31, 2019 |  | As of December 31, 2018
(in millions) | Gross Carrying Amount |  | Accumulated Amortization/Write-offs |  | Gross Carrying Amount |  | Accumulated Amortization/Write-offs
Amortizable intangible assets |  |  |  |  |  |  |
Technology-related | $ | 12,020 |  |  | $ | (5,706 | ) |  | $ | 10,197 |  |  | $ | (5,266 | )
Patents | 525 |  |  | (408 | ) |  | 520 |  |  | (393 | )
Other intangible assets | 1,754 |  |  | (1,081 | ) |  | 1,666 |  |  | (958 | )
| $ | 14,299 |  |  | $ | (7,195 | ) |  | $ | 12,383 |  |  | $ | (6,617 | )
Indefinite-lived intangible assets |  |  |  |  |  |  |
Goodwill | $ | 20,076 |  |  | $ | (9,900 | ) |  | $ | 17,811 |  |  | $ | (9,900 | )
In-process research and development (IPR&D) | 662 |  |  | — |  |  | 486 |  |  | — |
Technology-related | 120 |  |  | — |  |  | 120 |  |  | — |
| $ | 20,858 |  |  | $ | (9,900 | ) |  | $ | 18,417 |  |  | $ | (9,900 | )
In the third quarter of 2019, we performed our annual impairment test of all IPR&D projects and our indefinite-lived core technology assets and determined that the assets were not impaired. In addition, we verified the classification as indefinite-lived assets continues to be appropriate. Intangible asset impairment charges were $105 million in 2019, $35 million in 2018 and $4 million in 2017. Refer to Note A - Significant Accounting Policies for a discussion of key assumptions used in our goodwill and intangible asset impairment testing. Effective January 1, 2018, we reclassified our Neuromodulation operating segment and associated goodwill balance from our MedSurg reportable segment to our Rhythm and Neuro reportable segment. This change did not impact our total goodwill carrying value. Our seven core businesses are organized into three reportable segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Following our acquisition of BTG, which closed during the third quarter of 2019, we have included BTG’s Interventional Medicine business within our Peripheral Interventions operating segment, within the Cardiovascular reportable segment. We present BTG’s Specialty Pharmaceuticals business as a standalone operating segment alongside our reportable segments. The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:
(in millions) | MedSurg |  | Rhythm and Neuro |  | Cardiovascular |  | Specialty Pharmaceuticals |  | Total
Balance as of December 31, 2017 | $ | 2,877 |  |  | $ | 417 |  |  | $ | 3,704 |  |  | $ | — |  |  | $ | 6,998 |
Reportable segment revisions | (1,379 | ) |  | 1,379 |  |  | — |  |  | — |  |  | — |
Foreign currency fluctuations and other changes | (3 | ) |  | (22 | ) |  | (3 | ) |  | — |  |  | (29 | )
Goodwill acquired | 568 |  |  | 150 |  |  | 224 |  |  | — |  |  | 942 |
Balance as of December 31, 2018 | $ | 2,063 |  |  | $ | 1,924 |  |  | $ | 3,925 |  |  | $ | — |  |  | $ | 7,911 |
Foreign currency fluctuations and other changes | (1 | ) |  | — |  |  | 58 |  |  | 9 |  |  | 66 |
Goodwill acquired | — |  |  | 268 |  |  | 1,712 |  |  | 238 |  |  | 2,218 |
Goodwill divested | — |  |  | — |  |  | (19 | ) |  | — |  |  | (19 | )
Balance as of December 31, 2019 | $ | 2,061 |  |  | $ | 2,192 |  |  | $ | 5,676 |  |  | $ | 247 |  |  | $ | 10,176 |
We did not have any goodwill impairments in 2019, 2018 or 2017. Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2019 is as follows (in millions):
Fiscal Year |
2020 | $ | 787 |
2021 | 750 |
2022 | 722 |
2023 | 708 |
2024 | 672 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration